CD8A and cancer: For example, a vaccine designed with TDEs released by mouse cancer cell lines subjected to treatment with IFN-γ and interferon receptor factor-1 (IRF-1) was found to increase the number of infiltrated CD4+ and CD8+ T cells and reduce tumor size in C57BL/6J female mice transfected with Hepa 1-6 hepatoma cells or MC-38 colon carcinoma cells after 21 days of the exosome injection (46).